10:47 AM EDT, 04/24/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) was up near 13% on Wednesday after saying it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago from May 31 - June 4. It said updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external control arm will also be presented as a poster

According to a statement, the oral presentation will include new clinical data from the ongoing Phase 1/2 ABILITY-1 Study evaluating the company's candidate, MDNA11, as both a monotherapy and in combination with pembrolizumab (Merck's Keytruda) in patients with advanced or metastatic solid tumors.

The second abstract will provide new data analyses for bizaxofusp (formerly known as MDNA55) survival outcomes compared to a propensity matched external control arm (ECA) in nonresectable recurrent glioblastoma (rGBM).

Price: 1.76, Change: +0.21, Percent Change: +13.55